Cerus Corporation And Biomedica Foscama Group S.P.A. Enter Distribution Agreement For The INTERCEPT Blood System In Italy

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has entered into an agreement with Biomedica Foscama Group S.p.A (BFG) to distribute the INTERCEPT Blood System for plasma and platelets in Italy, with a goal of expanding the adoption of pathogen inactivation to improve blood safety. More than 200,000 platelet and over 400,000 plasma units are produced annually by Italian blood centers for transfusion.

Under the agreement, BFG will be the exclusive distributor for the INTERCEPT Blood System in Italy, Vatican City and San Marino. BFG’s responsibilities include the promotion, sale, deployment and support of INTERCEPT.

Help employers find you! Check out all the jobs and post your resume.